Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Inotropic therapy for end-stage heart failure patients.

Current treatment options in cardiovascular medicine

Toma M, Starling RC.
PMID: 20842563
Curr Treat Options Cardiovasc Med. 2010 Oct;12(5):409-19. doi: 10.1007/s11936-010-0090-9.

OPINION STATEMENT: Positive inotropic agents play an important role in the management of acute decompensated heart failure (HF) patients with reduced cardiac output and poor end-organ perfusion. However, despite their acute hemodynamic benefits, the role of inotropes in the...

Cite
Toma M, Starling RC. Inotropic therapy for end-stage heart failure patients. Curr Treat Options Cardiovasc Med. 2010;12(5):409-19doi: 10.1007/s11936-010-0090-9.
Toma, M., & Starling, R. C. (2010). Inotropic therapy for end-stage heart failure patients. Current treatment options in cardiovascular medicine, 12(5), 409-19. https://doi.org/10.1007/s11936-010-0090-9
Toma, Mustafa, and Starling, Randall C. "Inotropic therapy for end-stage heart failure patients." Current treatment options in cardiovascular medicine vol. 12,5 (2010): 409-19. doi: https://doi.org/10.1007/s11936-010-0090-9
Toma M, Starling RC. Inotropic therapy for end-stage heart failure patients. Curr Treat Options Cardiovasc Med. 2010 Oct;12(5):409-19. doi: 10.1007/s11936-010-0090-9. PMID: 20842563.
Copy Download .nbib Format: NLM
Retraction Note: Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function.

Intensive care medicine

[No authors listed]
PMID: 21604014
Intensive Care Med. 2011 Jul;37(7):1229. doi: 10.1007/s00134-011-2216-2.

No abstract available.

Cite
Retraction Note: Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intensive Care Med. 2011;37(7):1229doi: 10.1007/s00134-011-2216-2.
(2011). Retraction Note: Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intensive care medicine, 37(7), 1229. https://doi.org/10.1007/s00134-011-2216-2
"Retraction Note: Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function." Intensive care medicine vol. 37,7 (2011): 1229. doi: https://doi.org/10.1007/s00134-011-2216-2
Retraction Note: Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intensive Care Med. 2011 Jul;37(7):1229. doi: 10.1007/s00134-011-2216-2. PMID: 21604014.
Copy Download .nbib Format: NLM
Translational gap in pediatric septic shock management: an ESPNIC perspective.

Annals of intensive care

Morin L, Kneyber M, Jansen NJG, Peters MJ, Javouhey E, Nadel S, Maclaren G, Schlapbach LJ, Tissieres P.
PMID: 31254125
Ann Intensive Care. 2019 Jun 28;9(1):73. doi: 10.1186/s13613-019-0545-4.

BACKGROUND: The Surviving Sepsis Campaign and the American College of Critical Care Medicine guidelines have provided recommendations for the management of pediatric septic shock patients. We conducted a survey among the European Society of Pediatric and Neonatal Intensive Care...

Cite
Morin L, Kneyber M, Jansen NJG, et al. Translational gap in pediatric septic shock management: an ESPNIC perspective. Ann Intensive Care. 2019;9(1):73doi: 10.1186/s13613-019-0545-4.
Morin, L., Kneyber, M., Jansen, N. J. G., Peters, M. J., Javouhey, E., Nadel, S., Maclaren, G., Schlapbach, L. J., Tissieres, P. (2019). Translational gap in pediatric septic shock management: an ESPNIC perspective. Annals of intensive care, 9(1), 73. https://doi.org/10.1186/s13613-019-0545-4
Morin, Luc, et al. "Translational gap in pediatric septic shock management: an ESPNIC perspective." Annals of intensive care vol. 9,1 (2019): 73. doi: https://doi.org/10.1186/s13613-019-0545-4
Morin L, Kneyber M, Jansen NJG, Peters MJ, Javouhey E, Nadel S, Maclaren G, Schlapbach LJ, Tissieres P. Translational gap in pediatric septic shock management: an ESPNIC perspective. Ann Intensive Care. 2019 Jun 28;9(1):73. doi: 10.1186/s13613-019-0545-4. PMID: 31254125; PMCID: PMC6598895.
Copy Download .nbib Format: NLM
Retraction notice to "The role of enoximone in cardiac surgery" [Br J Anaesth 69 (1992) 45-50].

British journal of anaesthesia

Boldt J, Knothe C, Zickmann B, Ballesteros M, Russ W, Dapper F, Hempelmann G.
PMID: 32861404
Br J Anaesth. 2020 Sep;125(3):413. doi: 10.1016/j.bja.2020.07.029.

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief, Professor Hugh Hemmings, based on the recommendations of Justus-Liebig-University Giessen following an internal review of...

Cite
Boldt J, Knothe C, Zickmann B, et al. Retraction notice to "The role of enoximone in cardiac surgery" [Br J Anaesth 69 (1992) 45-50]. Br J Anaesth. 2020;125(3):413doi: 10.1016/j.bja.2020.07.029.
Boldt, J., Knothe, C., Zickmann, B., Ballesteros, M., Russ, W., Dapper, F., & Hempelmann, G. (2020). Retraction notice to "The role of enoximone in cardiac surgery" [Br J Anaesth 69 (1992) 45-50]. British journal of anaesthesia, 125(3), 413. https://doi.org/10.1016/j.bja.2020.07.029
Boldt, J, et al. "Retraction notice to "The role of enoximone in cardiac surgery" [Br J Anaesth 69 (1992) 45-50]." British journal of anaesthesia vol. 125,3 (2020): 413. doi: https://doi.org/10.1016/j.bja.2020.07.029
Boldt J, Knothe C, Zickmann B, Ballesteros M, Russ W, Dapper F, Hempelmann G. Retraction notice to "The role of enoximone in cardiac surgery" [Br J Anaesth 69 (1992) 45-50]. Br J Anaesth. 2020 Sep;125(3):413. doi: 10.1016/j.bja.2020.07.029. PMID: 32861404.
Copy Download .nbib Format: NLM
Effects of inhibitors of protein kinase C and phosphodiesterase on the contractile effects of endothelin in dog femoral artery.

Neurochemistry international

Cheng HC, Dage RC.
PMID: 20504732
Neurochem Int. 1991;18(4):497-501. doi: 10.1016/0197-0186(91)90146-5.

Endothelin-induced contraction in dog femoral artery strips was relaxed by a protein kinase C inhibitor (MDL 27,032), cyclic nucleotide phosphodiesterase (PDE) inhibitors (enoximone, piroximone, rolipram, 3-isobutyl-1-methylxanthine), an adenylcyclase activator (forskolin), a guanylcyclase activator (nitroprusside), but only slightly relaxed by...

Cite
Cheng HC, Dage RC. Effects of inhibitors of protein kinase C and phosphodiesterase on the contractile effects of endothelin in dog femoral artery. Neurochem Int. 1991;18(4):497-501doi: 10.1016/0197-0186(91)90146-5.
Cheng, H. C., & Dage, R. C. (1991). Effects of inhibitors of protein kinase C and phosphodiesterase on the contractile effects of endothelin in dog femoral artery. Neurochemistry international, 18(4), 497-501. https://doi.org/10.1016/0197-0186(91)90146-5
Cheng, H C, and Dage, R C. "Effects of inhibitors of protein kinase C and phosphodiesterase on the contractile effects of endothelin in dog femoral artery." Neurochemistry international vol. 18,4 (1991): 497-501. doi: https://doi.org/10.1016/0197-0186(91)90146-5
Cheng HC, Dage RC. Effects of inhibitors of protein kinase C and phosphodiesterase on the contractile effects of endothelin in dog femoral artery. Neurochem Int. 1991;18(4):497-501. doi: 10.1016/0197-0186(91)90146-5. PMID: 20504732.
Copy Download .nbib Format: NLM
Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report.

Canadian respiratory journal

Beute J, Boermans P, KleinJan A.
PMID: 34760031
Can Respir J. 2021 Nov 01;2021:7456208. doi: 10.1155/2021/7456208. eCollection 2021.

BACKGROUND: The population of uncontrolled asthma patients represents a large therapeutic burden. The PDE3-inhibitor enoximone is a strong and quick bronchodilator and is known to successfully treat life-threatening bronchial asthma (status asthmaticus). Translational mice models showed anti-inflammatory effects when...

Cite
Beute J, Boermans P, KleinJan A. Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report. Can Respir J. 2021;2021:7456208doi: 10.1155/2021/7456208.
Beute, J., Boermans, P., & KleinJan, A. (2021). Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report. Canadian respiratory journal, 20217456208. https://doi.org/10.1155/2021/7456208
Beute, Jan, et al. "Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report." Canadian respiratory journal vol. 2021 (2021): 7456208. doi: https://doi.org/10.1155/2021/7456208
Beute J, Boermans P, KleinJan A. Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report. Can Respir J. 2021 Nov 01;2021:7456208. doi: 10.1155/2021/7456208. eCollection 2021. PMID: 34760031; PMCID: PMC8575614.
Copy Download .nbib Format: NLM
The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients: Retraction.

Anesthesia and analgesia

[No authors listed]
PMID: 21451080
Anesth Analg. 2011 May;112(5):1109. doi: 10.1213/ANE.0b013e31821a937c. Epub 2011 Mar 30.

No abstract available.

Cite
The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients: Retraction. Anesth Analg. 2011;112(5):1109doi: 10.1213/ANE.0b013e31821a937c.
(2011). The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients: Retraction. Anesthesia and analgesia, 112(5), 1109. https://doi.org/10.1213/ANE.0b013e31821a937c
"The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients: Retraction." Anesthesia and analgesia vol. 112,5 (2011): 1109. doi: https://doi.org/10.1213/ANE.0b013e31821a937c
The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients: Retraction. Anesth Analg. 2011 May;112(5):1109. doi: 10.1213/ANE.0b013e31821a937c. Epub 2011 Mar 30. PMID: 21451080.
Copy Download .nbib Format: NLM
Retraction notice to "Haemodynamic effects of the phosphodiesterase inhibitor enoximone in comparison with dobutamine in esmolol-treated cardiac surgery patients" [Br J Anaesth 64 (1990) 611-6].

British journal of anaesthesia

Boldt J, Kling D, Zickmann B, Dapper F, Hempelmann G.
PMID: 32861402
Br J Anaesth. 2020 Sep;125(3):412. doi: 10.1016/j.bja.2020.07.027.

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief, Professor Hugh Hemmings, based on the recommendations of Justus-Liebig-University Giessen following an internal review of...

Cite
Boldt J, Kling D, Zickmann B, et al. Retraction notice to "Haemodynamic effects of the phosphodiesterase inhibitor enoximone in comparison with dobutamine in esmolol-treated cardiac surgery patients" [Br J Anaesth 64 (1990) 611-6]. Br J Anaesth. 2020;125(3):412doi: 10.1016/j.bja.2020.07.027.
Boldt, J., Kling, D., Zickmann, B., Dapper, F., & Hempelmann, G. (2020). Retraction notice to "Haemodynamic effects of the phosphodiesterase inhibitor enoximone in comparison with dobutamine in esmolol-treated cardiac surgery patients" [Br J Anaesth 64 (1990) 611-6]. British journal of anaesthesia, 125(3), 412. https://doi.org/10.1016/j.bja.2020.07.027
Boldt, J, et al. "Retraction notice to "Haemodynamic effects of the phosphodiesterase inhibitor enoximone in comparison with dobutamine in esmolol-treated cardiac surgery patients" [Br J Anaesth 64 (1990) 611-6]." British journal of anaesthesia vol. 125,3 (2020): 412. doi: https://doi.org/10.1016/j.bja.2020.07.027
Boldt J, Kling D, Zickmann B, Dapper F, Hempelmann G. Retraction notice to "Haemodynamic effects of the phosphodiesterase inhibitor enoximone in comparison with dobutamine in esmolol-treated cardiac surgery patients" [Br J Anaesth 64 (1990) 611-6]. Br J Anaesth. 2020 Sep;125(3):412. doi: 10.1016/j.bja.2020.07.027. PMID: 32861402.
Copy Download .nbib Format: NLM
(Oral) enoximone in asthma.

ERJ open research

Beute J.
PMID: 33263042
ERJ Open Res. 2020 Nov 02;6(4). doi: 10.1183/23120541.00319-2020. eCollection 2020 Oct.

No abstract available.

Cite
Beute J. (Oral) enoximone in asthma. ERJ Open Res. 2020;6(4)doi: 10.1183/23120541.00319-2020.
Beute, J. (2020). (Oral) enoximone in asthma. ERJ open research, 6(4), . https://doi.org/10.1183/23120541.00319-2020
Beute, Jan. "(Oral) enoximone in asthma." ERJ open research vol. 6,4 (2020). doi: https://doi.org/10.1183/23120541.00319-2020
Beute J. (Oral) enoximone in asthma. ERJ Open Res. 2020 Nov 02;6(4). doi: 10.1183/23120541.00319-2020. eCollection 2020 Oct. PMID: 33263042; PMCID: PMC7682675.
Copy Download .nbib Format: NLM
New strategies to control the inflammatory response in cardiac surgery.

Current opinion in anaesthesiology

Maharaj C, Laffey JG.
PMID: 17021527
Curr Opin Anaesthesiol. 2004 Feb;17(1):35-48. doi: 10.1097/00001503-200402000-00007.

PURPOSE OF REVIEW: To present and interpret data from recent clinical studies (July 2002-August 2003) of strategies to control the inflammatory response after cardiac surgery.RECENT FINDINGS: Off-pump coronary artery bypass techniques, which avoid the need for extracorporeal circulation, attenuate...

Cite
Maharaj C, Laffey JG. New strategies to control the inflammatory response in cardiac surgery. Curr Opin Anaesthesiol. 2004;17(1):35-48doi: 10.1097/00001503-200402000-00007.
Maharaj, C., & Laffey, J. G. (2004). New strategies to control the inflammatory response in cardiac surgery. Current opinion in anaesthesiology, 17(1), 35-48. https://doi.org/10.1097/00001503-200402000-00007
Maharaj, Chris, and Laffey, John G. "New strategies to control the inflammatory response in cardiac surgery." Current opinion in anaesthesiology vol. 17,1 (2004): 35-48. doi: https://doi.org/10.1097/00001503-200402000-00007
Maharaj C, Laffey JG. New strategies to control the inflammatory response in cardiac surgery. Curr Opin Anaesthesiol. 2004 Feb;17(1):35-48. doi: 10.1097/00001503-200402000-00007. PMID: 17021527.
Copy Download .nbib Format: NLM
PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells.

Frontiers in pharmacology

Beute J, Ganesh K, Nastiti H, Hoogenboom R, Bos V, Folkerts J, Schreurs MWJ, Hockman S, Hendriks RW, KleinJan A.
PMID: 32425769
Front Pharmacol. 2020 May 01;11:470. doi: 10.3389/fphar.2020.00470. eCollection 2020.

Epithelial mast cells are generally present in the airways of patients with allergic asthma that are inadequately controlled. Airway mast cells (MCs) are critically involved in allergic airway inflammation and contribute directly to the main symptoms of allergic patients....

Cite
Beute J, Ganesh K, Nastiti H, et al. PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells. Front Pharmacol. 2020;11:470doi: 10.3389/fphar.2020.00470.
Beute, J., Ganesh, K., Nastiti, H., Hoogenboom, R., Bos, V., Folkerts, J., Schreurs, M. W. J., Hockman, S., Hendriks, R. W., & KleinJan, A. (2020). PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells. Frontiers in pharmacology, 11470. https://doi.org/10.3389/fphar.2020.00470
Beute, Jan, et al. "PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells." Frontiers in pharmacology vol. 11 (2020): 470. doi: https://doi.org/10.3389/fphar.2020.00470
Beute J, Ganesh K, Nastiti H, Hoogenboom R, Bos V, Folkerts J, Schreurs MWJ, Hockman S, Hendriks RW, KleinJan A. PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells. Front Pharmacol. 2020 May 01;11:470. doi: 10.3389/fphar.2020.00470. eCollection 2020. PMID: 32425769; PMCID: PMC7206980.
Copy Download .nbib Format: NLM
Enoximone in status asthmaticus.

ERJ open research

Schulz O, Wiesner O, Welte T, Bollmann BA, Suhling H, Hoeper MM, Busch M.
PMID: 32280667
ERJ Open Res. 2020 Apr 06;6(1). doi: 10.1183/23120541.00367-2019. eCollection 2020 Jan.

No abstract available.

Cite
Schulz O, Wiesner O, Welte T, et al. Enoximone in status asthmaticus. ERJ Open Res. 2020;6(1)doi: 10.1183/23120541.00367-2019.
Schulz, O., Wiesner, O., Welte, T., Bollmann, B. A., Suhling, H., Hoeper, M. M., & Busch, M. (2020). Enoximone in status asthmaticus. ERJ open research, 6(1), . https://doi.org/10.1183/23120541.00367-2019
Schulz, Oscar, et al. "Enoximone in status asthmaticus." ERJ open research vol. 6,1 (2020). doi: https://doi.org/10.1183/23120541.00367-2019
Schulz O, Wiesner O, Welte T, Bollmann BA, Suhling H, Hoeper MM, Busch M. Enoximone in status asthmaticus. ERJ Open Res. 2020 Apr 06;6(1). doi: 10.1183/23120541.00367-2019. eCollection 2020 Jan. PMID: 32280667; PMCID: PMC7132035.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries